Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00405015
Other study ID # AR49653-4
Secondary ID EudraCT number 2
Status Completed
Phase Phase 2
First received November 28, 2006
Last updated August 23, 2010
Start date April 2007
Est. completion date October 2008

Study information

Verified date October 2008
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion-injury would improve the outcome of diabetic patients after a cardiovascular event. In the present study, we will use annexinA5 scintigraphy to address the following hypothesis:

Rosiglitazone reduces ischemia-reperfusion-injury in humans with insulin resistance.


Description:

Rationale: Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion-injury would improve the outcome of diabetic patients after a cardiovascular event. The thiazolidinedione derivatives are peroxisome proliferator-activated receptor-γ (PPARγ) ligands that are approved for the treatment of hyperglycemia in type 2 diabetes mellitus. Animal data suggest that PPARγ ligands can protect against ischemia-reperfusion-injury by improving insulin responsiveness. However, no human data on these beneficial effects are available. Recently, our group developed a human in vivo model to quantify ischemia-reperfusion-injury. In this model annexin A5 scintigraphy is used to visualize early and reversible cellular membrane changes that occur in the forearm skeletal muscle vascular bed after ischemic exercise. In the present study, we will use this approach to address the following hypothesis: Rosiglitazone reduces ischemia-reperfusion-injury in humans with insulin resistance, selected by using the criteria for the metabolic syndrome.

Study design: This is a single-center randomized, double blind, placebo-controlled crossover study with a washout period of 6 weeks.

Study population: Men and postmenopausal women, age 20-70 years with the metabolic syndrome.

Intervention: Every subject uses during 8 weeks rosiglitazone 4 mg bd and placebo bd. Week 8 and 22: assessment of ischemic-reperfusion injury with Technetium Annexin A5 Scintigraphy. Ischemic intervention: 10 minutes ischemia of the non-dominant arm with at the same time rhythmic contractions of the forearm and hand muscles.

Main study parameters/endpoints: Annexin targeting in the thenar muscle after ischemic exercise. The primary analysis is the difference in annexin targeting following 8 weeks of treatment with rosiglitazone 4 mg bd or placebo.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date October 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- At least 3 features of the metabolic syndrome (AHA/NHLBI).

- Willing and able to provide a signed and dated written informed consent.

- Men or postmenopausal women aged between 20 and 70 years.

Exclusion Criteria:

- Fasting glucose > 7,0 mmol/L or the use of hypoglycaemic agents. If fasting plasma glucose is between 6.1 and 7,0 mmol/L, an oral 75 g glucose test will be performed to exclude diabetes mellitus.

- Exposure to a PPAR-g agonist during the last 4 months or a documented significant hypersensitivity to a PPAR-g agonist.

- Participant in another study.

- Angina or heart failure (NYHA I-IV).

- Clinically significant liver disease (3 times the upper normal limit of ALAT, ASAT, AF, ?GT or LDH)

- Clinically significant anemia (male Hb < 6,9 mmol/L, female < 6,25 mmol/L)

- Creatinin clearance < 40 mL/min

- Alcohol or drug abuse.

- Any physical inability to perform the exercise protocol.

- Administration of any radio pharmacon for research purposes in the previous 5 years.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Drug:
rosiglitazone
Rosiglitazone 4 mg bidaily for 8 weeks

Locations

Country Name City State
Netherlands Clinical research Center Nijmegen Nijmegen

Sponsors (2)

Lead Sponsor Collaborator
Radboud University GlaxoSmithKline

Country where clinical trial is conducted

Netherlands, 

References & Publications (4)

Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 1997 Feb 15;126(4):296-306. Review. — View Citation

Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999 Sep 7;100(10):1134-46. Review. Erratum in: Circulation 2000 Apr 4;101(13):1629-31. — View Citation

Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27. — View Citation

Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 2005 Feb;54(2):554-62. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Annexin targeting in the thenar muscle after ischemic exercise. The primary analysis is the difference in annexin targeting following 8 weeks of treatment with rosiglitazone 4 mg bd or placebo.
Secondary The effect of rosiglitazone as compared to placebo on the HOMA-index.
Secondary Changes in vital signs, body weight, clinical laboratory parameters and adverse events monitoring during the study.
See also
  Status Clinical Trial Phase
Recruiting NCT05327348 - Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery Phase 3
Completed NCT00184912 - The Effect of Caffeine on Ischemic Preconditioning N/A
Recruiting NCT05585255 - Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury
Completed NCT05598177 - Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass Phase 4
Completed NCT04284592 - Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery N/A
Withdrawn NCT00441714 - Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise N/A
Completed NCT00248040 - Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation Phase 2
Completed NCT01486212 - Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers N/A
Recruiting NCT06097702 - A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants Phase 1
Completed NCT01073202 - Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation N/A
Completed NCT00224406 - Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation Phase 2
Completed NCT05246618 - FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation Phase 1/Phase 2
Completed NCT02118753 - The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium N/A
Completed NCT01739088 - Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery N/A
Completed NCT01040013 - Gut Oxygenation and Laparoscopy Phase 2
Suspended NCT00184847 - Adenosine Receptors Influence Ischemia-Reperfusion Injury N/A
Completed NCT01172171 - The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction Phase 2
Completed NCT00457405 - Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? Phase 4
Completed NCT00184821 - Ischemic Injury and Ischemic Preconditioning in Diabetes N/A
Not yet recruiting NCT00691613 - Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model N/A